Bioxytran (BIXT) Stock Price, News & Analysis

Company Overview

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Key Stats

• Today's Range: $0.11 to $0.12
• 50-Day Range: $0.08 to $0.12
• 52-Week Range: $0.07 to $0.19
• Volume: 12,897 shs
• Average Volume: 84,183 shs
• Market Capitalization: $20.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bioxytran Stock Analysis - MarketRank™

Bioxytran scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bioxytran.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioxytran is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioxytran is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of Bioxytran have been sold short.

Short Interest Ratio / Days to Cover

Bioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioxytran does not currently pay a dividend.

Dividend Growth

Bioxytran does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the outstanding shares of Bioxytran have been sold short.

Short Interest Ratio / Days to Cover

Bioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for BIXT on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioxytran insiders have not sold or bought any company stock.

Percentage Held by Insiders

70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.

BIXT Stock Analysis - Frequently Asked Questions

How have BIXT shares performed this year?

Bioxytran's stock was trading at $0.15 at the start of the year. Since then, BIXT stock has decreased by 23.3% and is now trading at $0.1150.
View the best growth stocks for 2024 here.

How do I buy shares of Bioxytran?

Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bioxytran own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX).

Company Calendar

• Today: 10/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BIXT
• CUSIP: N/A
• CIK: 1445815
• Web: www.bioxytraninc.com
• Phone: (617) 454-1199
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,280,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -2,417.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -5.75

Miscellaneous

• Outstanding Shares: 177,204,000
• Free Float: 53,387,000
• Market Cap: $20.38 million
• Optionable: Not Optionable
• Beta: -0.89